Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
2197–2232
Headlines
3528
Sources here
14
Companies here
26
Current section United States Drug Manufacturers - Specialty & Generic news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

SBI Securities Starts Takeda Pharmaceutical at Neutral with 5,400 Yen Price Target

SBI Securities initiated coverage on Takeda Pharmaceutical (4502.FU) with a Neutral rating and a price target of 5,400 yen. The Japanese pharmaceutical company's stock was trading at 5,744.00 JPY, down 0.43% for the day, as of the market close. The report from MT Newswires …

TAK main company
Sharemaestro market context Price above Trend Line 52 weeks +16.1% TAK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Is Rising Earnings Optimism Altering The Investment Case For Supernus Pharmaceuticals (SUPN)?

Supernus Pharmaceuticals recently drew attention after analysts became more optimistic about its upcoming August 4, 2026 earnings report, citing a positive Earnings ESP of 18.52% and the company's track record of exceeding consensus in its last two quarters. This shift in sentiment highlights how …

SUPN main company
Sharemaestro market context Price below Trend Line 52 weeks +7.6% SUPN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Collegium Pharmaceutical Inc (COLL) Financial Health: Profitability & Balance Sheet Analysis

Collegium Pharmaceutical Inc (COLL) currently has a financial score of 8.88, ranking 29th out of 155 in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company recently reported a quarterly revenue of $193.52 million, an 8.87% increase year-over-year, alongside a …

COLL main company
Sharemaestro market context Price below Trend Line 52 weeks -27.8% COLL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Collegium Pharmaceutical Inc. (COLL) Q4 2022 Earnings Report - Results, Call & Slides

This report details Collegium Pharmaceutical's (COLL) Q4 2022 earnings. The company reported actual EPS of $1.09, missing the consensus by less than $0.01, and actual revenue of $129.62 million, beating expectations by $4.40 million. The report includes details on the earnings announcement, an audio …

COLL main company
Sharemaestro market context Price below Trend Line 52 weeks -27.8% COLL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

ACB|Aurora Cannabis Inc|Price:2.730|Chg%:+0.060

TradingKey provides a comprehensive stock analysis for Aurora Cannabis Inc (ACB), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status. The analysis notes high institutional ownership and recent "Buy" ratings from analysts, with a target price of $32.00. Despite a sideways …

ACB main company
Sharemaestro market context Price above Trend Line 52 weeks -26.3% · Next-week setup negative 41.6% ACB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has announced that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) on behalf of investors who purchased securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis Inc. made false and …

ZTS main company
Sharemaestro market context Price below Trend Line 52 weeks -52.3% ZTS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BTAI|BioXcel Therapeutics Inc|Price:0.845|Chg%:-0.022

This article provides a comprehensive stock analysis of BioXcel Therapeutics Inc (BTAI), highlighting its relatively stable fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The company is actively developing neuroscience and immuno-oncology candidates, with analysts predominantly rating it as a "Buy" …

BTAI main company
Sharemaestro market context Price below Trend Line 52 weeks -76.1% · Next-week setup negative 36.4% BTAI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aytu Biopharma Inc (AYTU) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Aytu Biopharma Inc (AYTU) based on its current stock price and financial metrics. As of July 29, 2026, the company's valuation score is 8.95, ranking 65th in the Pharmaceuticals industry, with a P/E ratio of -0.45. Key …

AYTU main company
Sharemaestro market context Price below Trend Line 52 weeks +8.2% · Next-week setup negative 37.8% AYTU stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Elanco Animal Health Inc (ELAN) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Elanco Animal Health Inc (ELAN), noting its current score of 8.17, ranking 71 out of 155 in the Pharmaceuticals industry. The company's financial status is described as weak, despite high operating efficiency. Elanco recently reported a …

ELAN main company
Sharemaestro market context Price below Trend Line 52 weeks +32.2% ELAN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Supernus Pharmaceuticals (SUPN) Could Be 25% Undervalued On Rising Earnings Expectations

Supernus Pharmaceuticals (SUPN) is considered undervalued by 25% due to rising earnings expectations, with a positive Earnings ESP of 18.52% and a history of beating estimates. Analysts peg the fair value at $62.83, significantly higher than its current share price of $46.98. This valuation …

SUPN main company
Sharemaestro market context Price below Trend Line 52 weeks +7.6% SUPN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Aurora shareholders will vote on four items at Aug. 7 virtual meeting

Institutional Shareholder Services (ISS) has recommended that Aurora Cannabis shareholders vote FOR all resolutions at the upcoming 2026 Annual General Meeting (AGM) on August 7, 2026. Shareholders will vote on fixing the board size at five directors, electing directors, appointing the auditor, and a …

ACB main company
Sharemaestro market context Price above Trend Line 52 weeks -26.3% · Next-week setup negative 41.6% ACB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

PRGO|Perrigo Company PLC|Price:10.130|Chg%:+0.040

This article provides a comprehensive stock analysis of Perrigo Company PLC (PRGO), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. While institutional ownership is very high and analysts largely rate it as "Hold," the stock price is …

PRGO main company
Sharemaestro market context Price above Trend Line 52 weeks -42.2% PRGO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Price to book ratio of United Therapeutics Corporation – HAM:UTH

This page from TradingView displays financial information, specifically the price-to-book ratio, for United Therapeutics Corporation (UTH) on the Hamburg Stock Exchange. The market appears to be closed with no trades showing. The article provides a chart or table for the period, value, and change …

UTHR main company
Sharemaestro market context Trend signal ended 52 weeks +60.1% · Next-week setup positive 58.0% UTHR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Pacira Biosciences Inc (PCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Pacira Biosciences Inc (PCRX), detailing its current risk score, beta value, and various volatility metrics. The company ranks 49th out of 155 in the pharmaceuticals industry with a risk assessment score of 6.68 and a beta of …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Alvotech SA (ALVO) Cash Flow

This article provides a detailed look at Alvotech SA's (ALVO) cash flow statement, including operating, investing, and financing cash flow data presented quarterly and annually. It includes specific financial figures for these categories over several fiscal quarters, highlighting changes year-over-year. The article also features …

ALVO main company
Sharemaestro market context Price above Trend Line 52 weeks -52.0% · Next-week setup negative 43.6% ALVO stored weekly price path from 22 Aug 2025 to 14 Aug 2026

BFRI|Biofrontera Inc|Price:1.050|Chg%:-0.040

This article provides a detailed financial overview of Biofrontera Inc (BFRI), including its latest earnings report from May 14, 2026, with an EPS forecast of -0.12 and revenue forecast of 10.25M. It presents comprehensive quarterly and annual financial statements such as income statements, balance …

BFRI main company
Sharemaestro market context Trend signal active 52 weeks +34.9% · Next-week setup negative 42.9% BFRI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Regencell Bioscience Holdings Ltd

This article provides an overview of Regencell Bioscience Holdings Ltd (RGC), including its current stock price, market cap, and stock performance. It notes that revenue breakdown data by business segment and region have not yet been disclosed by the company. The page serves as …

RGC main company
Sharemaestro market context Price below Trend Line 52 weeks -57.4% · Next-week setup negative 33.9% RGC stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Redhill Biopharma Ltd (RDHL) Institutional Confidence

This article from TradingKey provides an overview of Redhill Biopharma Ltd's (RDHL) institutional confidence, a component of its overall stock score. It lists institutional holdings and changes, showing that while some firms like Yorkville Advisors Global hold significant shares without recent changes, others like …

RDHL main company
Sharemaestro market context Price below Trend Line 52 weeks -54.2% · Next-week setup negative 35.9% RDHL stored weekly price path from 22 Aug 2025 to 14 Aug 2026

TherapeuticsMD Inc (TXMD) Income Statement

This article provides a detailed income statement for TherapeuticsMD Inc (TXMD), offering both quarterly and annual financial data spanning several years. It includes key financial metrics such as total revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The page …

TXMD main company
Sharemaestro market context Price below Trend Line 52 weeks +88.2% · Next-week setup negative 41.1% TXMD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Sonoma Pharmaceuticals Inc (SNOA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of the shareholder structure of Sonoma Pharmaceuticals Inc (SNOA), detailing major shareholders and institutional holdings. It lists the proportion of shares held by entities like DRW Securities, Vanguard Capital Management, and Geode Capital Management, as well as various shareholder …

SNOA main company
Sharemaestro market context Price below Trend Line 52 weeks -74.5% · Next-week setup negative 43.9% SNOA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Xeris Biopharma Holdings Inc (XERS) has an earnings forecast score of 8.57, ranking 26th in the Pharmaceuticals industry. Analysts have an average price target of $10.00 for XERS, with a consensus "Buy" rating based on 7 analysts. The expected revenue for the next quarter …

XERS main company
Sharemaestro market context Trend signal active 52 weeks +11.0% · Next-week setup positive 55.8% XERS stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Talphera Inc (TLPH) Institutional Confidence

Talphera Inc (TLPH) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 40.00%, showing a 0.70% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.48% of outstanding shares.

TLPH main company
Sharemaestro market context Trend signal active 52 weeks +149.6% · Next-week setup negative 38.8% TLPH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context